BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32586407)

  • 1. The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study.
    Guo J; Ren Z; Li J; Li T; Liu S; Yu Z
    Arthritis Res Ther; 2020 Jun; 22(1):159. PubMed ID: 32586407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
    Wakiya R; Ueeda K; Shimada H; Nakashima S; Kameda T; Miyatake N; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Clin Rheumatol; 2022 Nov; 41(11):3345-3353. PubMed ID: 35849246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
    J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer].
    Guo JY; Ren ZG; Xuan YY; Li TF; Liu XJ; Niu CZ; Li JY; Liu SY
    Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):218-221. PubMed ID: 32146749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine might reduce risk of incident endometriosis in patients with systemic lupus erythematosus: A retrospective population-based cohort study.
    Chen FY; Chen SW; Chen X; Huang JY; Ye Z; Wei JC
    Lupus; 2021 Sep; 30(10):1609-1616. PubMed ID: 34259057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.
    Esteve-Valverde E; Tapiz-Reula A; Ruiz D; Alijotas-Reig J
    Rheumatol Int; 2020 May; 40(5):777-783. PubMed ID: 31865445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
    Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
    Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study.
    Hsu CY; Lin MS; Su YJ; Cheng TT; Lin YS; Chen YC; Chiu WC; Chen TH
    Rheumatology (Oxford); 2017 Apr; 56(4):620-628. PubMed ID: 28039419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
    Takamasu E; Yokogawa N; Shimada K; Sugii S
    Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
    Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
    Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
    JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.